Publications 2024

Hanekamp BA, Virdee PS, Goh V, Jones M, Hvass Hansen R, Hjorth Johannesen H, Schulz A, Serup-Hansen E, Guren MG, Muirhead R (2024)
Diffusion-weighted magnetic resonance imaging as an early prognostic marker of chemoradiotherapy response in squamous cell carcinoma of the anus: An individual patient data meta-analysis
Phys Imaging Radiat Oncol, 31, 100618
DOI 10.1016/j.phro.2024.100618, PubMed 39188809

Os SS, Skipar K, Skovlund E, Hompland I, Hellebust TP, Guren MG, Lindemann K, Nakken ES (2024)
Survival prediction in patients with gynecological cancer irradiated for brain metastases
Acta Oncol, 63, 206-212
DOI 10.2340/1651-226X.2023.34899, PubMed 38647023

Ree AH, Høye E, Esbensen Y, Beitnes AR, Negård A, Bernklev L, Tetlie LK, Fretland ÅA, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Nilsen HL, Flatmark K, Meltzer S (2024)
Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade
Oncoimmunology, 13 (1), 2372886
DOI 10.1080/2162402X.2024.2372886, PubMed 38952672

Ree AH, Šaltytė Benth J, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Johansen C, Negård A, Bjørnetrø T, Nilsen HL, Berg JP, Flatmark K, Meltzer S (2024)
First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial
Br J Cancer, 130 (12), 1921-1928
DOI 10.1038/s41416-024-02696-6, PubMed 38664577

Samuel R, Knight SR, Adams R, Das P, Dorth J, Finch D, Guren MG, Hawkins MA, Moug S, Rajdev L, Sebag-Montefiore D, Renehan AG, Fish R, plus the CORMAC-2 collaborators (2024)
International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome set
EClinicalMedicine, 78, 102939
DOI 10.1016/j.eclinm.2024.102939, PubMed 39720423

Slørdahl KS, Balto A, Guren MG, Wibe A, Kørner H, Norderval S, Gjelsvik YM, Myklebust TÅ, Larsen IK (2024)
Patient-reported outcomes after treatment for rectal cancer-A prospective nationwide study
Colorectal Dis (in press)
DOI 10.1111/codi.17231, PubMed 39515999

Sodergren SC, Hurley-Wallace A, Vassiliou V, Alkhaffaf B, Batsaikhan B, Darlington AS, Fleitas-Kanonnikof T, Guren MG, Honda M, Kim YW, Kim S, Krishnamurthy MN, Loh SY, Turhal NS, Zhou J, Dennis K, Krishnatry R, Terashima M, Tsironis G, Yoshikawa T, Terada M, EORTC Quality of Life Group (2024)
Revisiting the use of the EORTC QLQ-STO22 to assess health-related quality of life of patients with gastric cancer: incorporating updated treatment options and cross-cultural perspectives
Gastric Cancer, 27 (4), 722-734
DOI 10.1007/s10120-024-01492-8, PubMed 38668819

Willmann J, Balermpas P, Rimner A, Appelt AL, Vasquez Osorio EM, Rønde HS, Day M, Embring A, Gabryś D, Guren MG, Hoskin P, Massaccesi M, Mayo C, Murray L, Nieder C, Guckenberger M, Andratschke N (2024)
Ongoing prospective studies on reirradiation: A systematic review of a clinical trials database
Radiother Oncol, 202, 110624
DOI 10.1016/j.radonc.2024.110624, PubMed 39532233

Publications 2023

Acosta Roa AM, Skingen VE, Rekstad BL, Undseth C, Rusten E, Hernes E, Guren MG, Malinen E (2023)
Stability of metabolic tumor volume may enable radiotherapy dose painting in anal cancer
Phys Med, 114, 103151
DOI 10.1016/j.ejmp.2023.103151, PubMed 37813051

Hanekamp BA, Viktil E, Slørdahl KS, Dormagen JB, Kløw NE, Malinen E, Brunborg C, Guren MG, Schulz A (2023)
Magnetic resonance imaging of anal cancer: tumor characteristics and early prediction of treatment outcome
Strahlenther Onkol, 200 (1), 19-27
DOI 10.1007/s00066-023-02114-5, PubMed 37429949

Nilsson MP, Undseth C, Albertsson P, Eidem M, Havelund BM, Johannsson J, Johnsson A, Radu C, Serup-Hansen E, Spindler KL, Zakrisson B, Guren MG, Kronborg C (2023)
Nordic anal cancer (NOAC) group consensus guidelines for risk-adapted delineation of the elective clinical target volume in anal cancer
Acta Oncol, 62 (8), 897-906
DOI 10.1080/0284186X.2023.2240490, PubMed 37504978

Niyoteka S, Seban RD, Rouhi R, Scarsbrook A, Genestie C, Classe M, Carré A, Sun R, La Greca Saint-Esteven A, Chargari C, McKenna J, McDermott G, Malinen E, Tanadini-Lang S, Guckenberger M, Guren MG, Lemanski C, Deutsch E, Robert C (2023)
A common [18F]-FDG PET radiomic signature to predict survival in patients with HPV-induced cancers
Eur J Nucl Med Mol Imaging, 50 (13), 4010-4023
DOI 10.1007/s00259-023-06320-2, PubMed 37632562

Rowsell A, Sodergren SC, Vassiliou V, Darlington AS, Guren MG, Alkhaffaf B, Moorbey C, Dennis K, Terada M (2023)
Correction to: Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences
Gastric Cancer, 26 (1), 167
DOI 10.1007/s10120-022-01346-1, PubMed 36269499

Publications 2022

Bahadoer RR, Bastiaannet E, Peeters KCMJ, van Eycken E, Verbeeck J, Guren MG, Kørner H, Martling A, Johansson R, van de Velde CJH, Dekker JWT (2022)
The survival gap between young and older patients after surgical resection for colorectal cancer remains largely based on early mortality: A EURECCA comparison of four European countries
J Geriatr Oncol, 13 (6), 803-812
DOI 10.1016/j.jgo.2022.04.011, PubMed 35527207

Dijkstra EA, Hospers GAP, Kranenbarg EM, Fleer J, Roodvoets AGH, Bahadoer RR, Guren MG, Tjalma JJJ, Putter H, Crolla RMPH, Hendriks MP, Capdevila J, Radu C, van de Velde CJH, Nilsson PJ, Glimelius B, van Etten B, Marijnen CAM (2022)
Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer - The RAPIDO trial
Radiother Oncol, 171, 69-76
DOI 10.1016/j.radonc.2022.04.013, PubMed 35447283

Falk P, Severin M, Berglund Å, Guren MG, Hofsli E, Österlund P, Tandberg A, Eberhard J, Sorbye H (2022)
Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer
Cancer Treat Res Commun, 31, 100517
DOI 10.1016/j.ctarc.2022.100517, PubMed 35114500

Franco P, Segelov E, Johnsson A, Riechelmann R, Guren MG, Das P, Rao S, Arnold D, Spindler KG, Deutsch E, Krengli M, Tombolini V, Sebag-Montefiore D, De Felice F (2022)
A Machine-Learning-Based Bibliometric Analysis of the Scientific Literature on Anal Cancer
Cancers (Basel), 14 (7)
DOI 10.3390/cancers14071697, PubMed 35406469

Kørner H, Guren MG, Larsen IK, Haugen DF, Søreide K, Kørner LR, Søreide JA (2022)
Characteristics and fate of patients with rectal cancer not entering a curative-intent treatment pathway: A complete nationwide registry cohort of 3,304 patients
Eur J Surg Oncol, 48 (8), 1831-1839
DOI 10.1016/j.ejso.2022.04.013, PubMed 35527055

Meltzer S, Negård A, Bakke KM, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Flatmark K, Ree AH (2022)
Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
Br J Cancer, 127 (12), 2227-2233
DOI 10.1038/s41416-022-02004-0, PubMed 36229579

Nilssen Y, Brustugun OT, Eriksen MT, Guren MG, Haug ES, Naume B, Schlichting E, Møller B (2022)
Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015-2016
BMC Cancer, 22 (1), 220
DOI 10.1186/s12885-022-09306-9, PubMed 35227226

Rao S, Anandappa G, Capdevila J, Dahan L, Evesque L, Kim S, Saunders MP, Gilbert DC, Jensen LH, Samalin E, Spindler KL, Tamberi S, Demols A, Guren MG, Arnold D, Fakih M, Kayyal T, Cornfeld M, Tian C, Catlett M, Smith M, Spano JP (2022)
A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)
ESMO Open, 7 (4), 100529
DOI 10.1016/j.esmoop.2022.100529, PubMed 35816951

Rowsell A, Sodergren SC, Vassiliou V, Darlington AS, Guren MG, Alkhaffaf B, Moorbey C, Dennis K, Terada M (2022)
Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences
Gastric Cancer, 25 (4), 665-677
DOI 10.1007/s10120-022-01309-6, PubMed 35689705

Segelov E, Guren MG, Sebag-Montefiore D, Rao S, Johnsson A, Franco P, Deutsch E, Arnold D, Spindler KG (2022)
"Global Multidisciplinary Team Meetings": Challenging Cases Virtual Forums from the International Multidisciplinary Anal Cancer Conference (IMACC)
Clin Colorectal Cancer, 21 (3), 175-187
DOI 10.1016/j.clcc.2022.02.006, PubMed 35346604

Sodergren SC, Johnson CD, Gilbert A, Darlington AS, Cocks K, Guren MG, Rivin Del Campo E, Brannan C, Christensen P, Chu W, Chung H, Dennis K, Desideri I, Gilbert DC, Glynne-Jones R, Jefford M, Johansson M, Johnsson A, Juul T, Kardamakis D, Lai-Kwon J, McFarlane V, Miguel IMC, Nugent K, Peters F et al. (2022)
International Validation of the EORTC QLQ-ANL27, a Field Study to Test the Anal Cancer-Specific Health-Related Quality-of-Life Questionnaire
Int J Radiat Oncol Biol Phys, 115 (5), 1155-1164
DOI 10.1016/j.ijrobp.2022.11.002, PubMed 36402360

Theophanous S, Lønne PI, Choudhury A, Berbee M, Dekker A, Dennis K, Dewdney A, Gambacorta MA, Gilbert A, Guren MG, Holloway L, Jadon R, Kochhar R, Mohamed AA, Muirhead R, Parés O, Raszewski L, Roy R, Scarsbrook A, Sebag-Montefiore D, Spezi E, Spindler KG, van Triest B, Vassiliou V, Malinen E et al. (2022)
Development and validation of prognostic models for anal cancer outcomes using distributed learning: protocol for the international multi-centre atomCAT2 study
Diagn Progn Res, 6 (1), 14
DOI 10.1186/s41512-022-00128-8, PubMed 35922837

Publications 2021

Bahadoer RR, Bastiaannet E, Claassen YHM, van der Mark M, van Eycken E, Verbeeck J, Guren MG, Kørner H, Martling A, Johansson R, van de Velde CJH, Dekker JWT (2021)
One-year excess mortality and treatment in surgically treated patients with colorectal cancer: A EURECCA European comparison
Eur J Surg Oncol, 47 (7), 1651-1660
DOI 10.1016/j.ejso.2021.01.011, PubMed 33518367

Bruun J, Eide PW, Bergsland CH, Bruck O, Svindland A, Arjama M, Välimäki K, Bjørnslett M, Guren MG, Kallioniemi O, Nesbakken A, Lothe RA, Pellinen T (2021)
E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models
Mol Oncol, 16 (12), 2312-2329
DOI 10.1002/1878-0261.13159, PubMed 34890102

Choudhury A, Theophanous S, Lønne PI, Samuel R, Guren MG, Berbee M, Brown P, Lilley J, van Soest J, Dekker A, Gilbert A, Malinen E, Wee L, Appelt AL (2021)
Predicting outcomes in anal cancer patients using multi-centre data and distributed learning - A proof-of-concept study
Radiother Oncol, 159, 183-189
DOI 10.1016/j.radonc.2021.03.013, PubMed 33753156

Groendahl AR, Moe YM, Kaushal CK, Huynh BN, Rusten E, Tomic O, Hernes E, Hanekamp B, Undseth C, Guren MG, Malinen E, Futsaether CM (2021)
Deep learning-based automatic delineation of anal cancer gross tumour volume: a multimodality comparison of CT, PET and MRI
Acta Oncol, 61 (1), 89-96
DOI 10.1080/0284186X.2021.1994645, PubMed 34783610

Guren MG, Sebag-Montefiore D, Franco P, Johnsson A, Segelov E, Deutsch E, Rao S, Spindler KG, Arnold D (2021)
Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research: Perspectives of Research Needs in Anal Cancer
Clin Colorectal Cancer, 20 (4), 279-287
DOI 10.1016/j.clcc.2021.09.006, PubMed 34645589

Hamfjord J, Myklebust TÅ, Larsen IK, Kure EH, Glimelius B, Guren TK, Tveit KM, Guren MG (2021)
Survival Trends of Right- and Left-Sided Colon Cancer across Four Decades: A Norwegian Population-Based Study
Cancer Epidemiol Biomarkers Prev, 31 (2), 342-351
DOI 10.1158/1055-9965.EPI-21-0555, PubMed 34853022

Kryeziu K, Moosavi SH, Bergsland CH, Guren MG, Eide PW, Totland MZ, Lassen K, Abildgaard A, Nesbakken A, Sveen A, Lothe RA (2021)
Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases
J Transl Med, 19 (1), 384
DOI 10.1186/s12967-021-03062-3, PubMed 34496878

Moosavi SH, Eide PW, Eilertsen IA, Brunsell TH, Berg KCG, Røsok BI, Brudvik KW, Bjørnbeth BA, Guren MG, Nesbakken A, Lothe RA, Sveen A (2021)
De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity
Genome Med, 13 (1), 143
DOI 10.1186/s13073-021-00956-1, PubMed 34470666

Nilssen Y, Eriksen MT, Guren MG, Møller B (2021)
Factors associated with emergency-onset diagnosis, time to treatment and type of treatment in colorectal cancer patients in Norway
BMC Cancer, 21 (1), 757
DOI 10.1186/s12885-021-08415-1, PubMed 34187404

Osterman E, Ekström J, Sjöblom T, Kørner H, Myklebust TÅ, Guren MG, Glimelius B (2021)
Accurate population-based model for individual prediction of colon cancer recurrence
Acta Oncol, 60 (10), 1241-1249
DOI 10.1080/0284186X.2021.1953138, PubMed 34279175

Pilleron S, Charvat H, Araghi M, Arnold M, Fidler-Benaoudia MM, Bardot A, Guren MG, Tervonen H, Little A, O'Connell DL, Gavin A, De P, Thomsen LA, Moller B, Jackson C, Bucher O, Walsh PM, Vernon S, Bray F, Soerjomataram I (2021)
Age disparities in stage-specific colon cancer survival across seven countries: An International Cancer Benchmarking Partnership SURVMARK-2 population-based study. (vol 148, 1575, 2021)
Int. J. Cancer, 149 (6), E9
DOI 10.1002/ijc.33717

Rao S, Guren MG, Khan K, Brown G, Renehan AG, Steigen SE, Deutsch E, Martinelli E, Arnold D, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org (2021)
Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up^☆
Ann Oncol, 32 (9), 1087-1100
DOI 10.1016/j.annonc.2021.06.015, PubMed 34175386

REACCT Collaborative, Zaborowski AM, Abdile A, Adamina M, Aigner F, d'Allens L, Allmer C, Álvarez A, Anula R, Andric M, Atallah S, Bach S, Bala M, Barussaud M, Bausys A, Bebington B, Beggs A, Bellolio F, Bennett MR, Berdinskikh A, Bevan V, Biondo S, Bislenghi G, Bludau M, Boutall A et al. (2021)
Characteristics of Early-Onset vs Late-Onset Colorectal Cancer: A Review
JAMA Surg, 156 (9), 865-874
DOI 10.1001/jamasurg.2021.2380, PubMed 34190968

Rønde HS, Kallehauge JF, Kronborg CJS, Nyvang L, Rekstad BL, Hanekamp BA, Appelt AL, Guren MG, Spindler KLS (2021)
Intensity modulated proton therapy planning study for organ at risk sparing in rectal cancer re-irradiation
Acta Oncol, 60 (11), 1436-1439
DOI 10.1080/0284186X.2021.1953139, PubMed 34264785

Slørdahl KS, Klotz D, Olsen JÅ, Skovlund E, Undseth C, Abildgaard HL, Brændengen M, Nesbakken A, Larsen SG, Hanekamp BA, Holmboe L, Tvedt R, Sveen A, Lothe RA, Malinen E, Kaasa S, Guren MG (2021)
Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer
Acta Oncol, 60 (7), 921-930
DOI 10.1080/0284186X.2021.1918763, PubMed 33966592

Torstveit AH, Løyland B, Grov EK, Guren M, Paul SM, Ritchie C, Vistad I, Miaskowski C, Utne I (2021)
Distinctions Between Self-Report and Performance-Based Measures of Physical Function in Older Patients Prior to Chemotherapy
Cancer Nurs, 44 (6), E735-E744
DOI 10.1097/NCC.0000000000000964, PubMed 34183518

Torstveit AH, Miaskowski C, Løyland B, Grov EK, Guren MG, Ritchie CS, Paul SM, Kleven AG, Utne I (2021)
Common and distinct characteristics associated with self-reported functional status in older patients with cancer receiving chemotherapy
Eur J Oncol Nurs, 54, 102033
DOI 10.1016/j.ejon.2021.102033, PubMed 34537538

Publications 2020

Al-Haidari G, Skovlund E, Undseth C, Rekstad BL, Larsen SG, Åsli LM, Dueland S, Malinen E, Guren MG (2020)
Re-irradiation for recurrent rectal cancer - a single-center experience
Acta Oncol, 59 (5), 534-540
DOI 10.1080/0284186X.2020.1725111, PubMed 32056476

Araghi M, Arnold M, Rutherford MJ, Guren MG, Cabasag CJ, Bardot A, Ferlay J, Tervonen H, Shack L, Woods RR, Saint-Jacques N, De P, McClure C, Engholm G, Gavin AT, Morgan E, Walsh PM, Jackson C, Porter G, Møller B, Bucher O, Eden M, O'Connell DL, Bray F, Soerjomataram I (2020)
Colon and rectal cancer survival in seven high-income countries 2010-2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project)
Gut, 70 (1), 114-126
DOI 10.1136/gutjnl-2020-320625, PubMed 32482683

Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, Roodvoets AGH, Nagtegaal ID, Beets-Tan RGH, Blomqvist LK, Fokstuen T, Ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP, RAPIDO collaborative investigators (2020)
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
Lancet Oncol, 22 (1), 29-42
DOI 10.1016/S1470-2045(20)30555-6, PubMed 33301740

Bergsland CH, Bruun J, Guren MG, Svindland A, Bjørnslett M, Smeby J, Hektoen M, Kolberg M, Domingo E, Pellinen T, Tomlinson I, Kerr D, Church DN, Nesbakken A, Sveen A, Lothe RA (2020)
Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer
ESMO Open, 5 (6), e001040
DOI 10.1136/esmoopen-2020-001040, PubMed 33219056

Breugom AJ, Bastiaannet E, Guren MG, Kørner H, Boelens PG, Dekker FW, Kapiteijn E, Gelderblom H, Larsen IK, Liefers GJ, van de Velde CJH (2020)
Treatment strategies and overall survival for incurable metastatic colorectal cancer - A EURECCA international comparison including 21,196 patients from the Netherlands and Norway
Eur J Surg Oncol, 46 (6), 1167-1173
DOI 10.1016/j.ejso.2020.02.005, PubMed 32151531

Bruun J, Kryeziu K, Eide PW, Moosavi SH, Eilertsen IA, Langerud J, Røsok B, Totland MZ, Brunsell TH, Pellinen T, Saarela J, Bergsland CH, Palmer HG, Brudvik KW, Guren T, Dienstmann R, Guren MG, Nesbakken A, Bjørnbeth BA, Sveen A, Lothe RA (2020)
Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity
Clin Cancer Res, 26 (15), 4107-4119
DOI 10.1158/1078-0432.CCR-19-3637, PubMed 32299813

Dahl O, Myklebust MP, Dale JE, Leon O, Serup-Hansen E, Jakobsen A, Pfeiffer P, Løes IM, Pfeffer F, Spindler KG, Guren MG, Glimelius B, Johnsson A (2020)
Evaluation of the stage classification of anal cancer by the TNM 8th version versus the TNM 7th version
Acta Oncol, 59 (9), 1016-1023
DOI 10.1080/0284186X.2020.1778180, PubMed 32574087

Frydenberg H, Harsem NK, Ofigsbø Å, Skoglund H, Brændengen M, Kaasa S, Guren MG (2020)
Chemotherapy During Pregnancy for Advanced Colon Cancer: A Case Report
Clin Colorectal Cancer, 19 (2), 141-144
DOI 10.1016/j.clcc.2020.02.013, PubMed 32222353

Kværner AS, Harnæs H, Alavi DH, Bärebring L, Henriksen HB, Guren MG, Lauritzen PM, Eggesbø HB, Wiedswang G, Smeland S, Blomhoff R (2020)
Should calculation of chemotherapy dosage for bowel cancer be based on body composition?
Tidsskr Nor Laegeforen, 140 (8)
DOI 10.4045/tidsskr.19.0769, PubMed 32463187

Marijnen CAM, Peters FP, Rödel C, Bujko K, Haustermans K, Fokas E, Glynne-Jones R, Valentini V, Spindler KG, Guren MG, Maingon P, Calvo FA, Pares O, Glimelius B, Sebag-Montefiore D (2020)
International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic
Radiother Oncol, 148, 213-215
DOI 10.1016/j.radonc.2020.03.039, PubMed 32342861

Pilleron S, Charvat H, Araghi M, Arnold M, Fidler-Benaoudia MM, Bardot A, Grønlie Guren M, Tervonen H, Little A, O'Connell DL, Gavin A, De P, Aagard Thomsen L, Møller B, Jackson C, Bucher O, Walsh PM, Vernon S, Bray F, Soerjomataram I (2020)
Age disparities in stage-specific colon cancer survival across seven countries: An International Cancer Benchmarking Partnership SURVMARK-2 population-based study
Int J Cancer, 148 (7), 1575-1585
DOI 10.1002/ijc.33326, PubMed 33006395

Rao S, Sclafani F, Eng C, Adams RA, Guren MG, Sebag-Montefiore D, Benson A, Bryant A, Peckitt C, Segelov E, Roy A, Seymour MT, Welch J, Saunders MP, Muirhead R, O'Dwyer P, Bridgewater J, Bhide S, Glynne-Jones R, Arnold D, Cunningham D (2020)
International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct
J Clin Oncol, 38 (22), 2510-2518
DOI 10.1200/JCO.19.03266, PubMed 32530769

Smeby J, Kryeziu K, Berg KCG, Eilertsen IA, Eide PW, Johannessen B, Guren MG, Nesbakken A, Bruun J, Lothe RA, Sveen A (2020)
Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity
EBioMedicine, 59, 102923
DOI 10.1016/j.ebiom.2020.102923, PubMed 32799124

Publications 2019

Araghi M, Soerjomataram I, Bardot A, Ferlay J, Cabasag CJ, Morrison DS, De P, Tervonen H, Walsh PM, Bucher O, Engholm G, Jackson C, McClure C, Woods RR, Saint-Jacques N, Morgan E, Ransom D, Thursfield V, Møller B, Leonfellner S, Guren MG, Bray F, Arnold M (2019)
Changes in colorectal cancer incidence in seven high-income countries: a population-based study
Lancet Gastroenterol Hepatol, 4 (7), 511-518
DOI 10.1016/S2468-1253(19)30147-5, PubMed 31105047

Ben-Aharon I, Goshen-Lago T, Fontana E, Smyth E, Guren M, Caballero C, Lordick F (2019)
Social networks for young patients with cancer: the time for system agility
Lancet Oncol, 20 (6), 765
DOI 10.1016/S1470-2045(19)30346-8, PubMed 31162090

Brunsell TH, Cengija V, Sveen A, Bjørnbeth BA, Røsok BI, Brudvik KW, Guren MG, Lothe RA, Abildgaard A, Nesbakken A (2019)
Heterogeneous radiological response to neoadjuvant therapy is associated with poor prognosis after resection of colorectal liver metastases
Eur J Surg Oncol, 45 (12), 2340-2346
DOI 10.1016/j.ejso.2019.07.017, PubMed 31350075

Brunsell TH, Sveen A, Bjørnbeth BA, Røsok BI, Danielsen SA, Brudvik KW, Berg KCG, Johannessen B, Cengija V, Abildgaard A, Guren MG, Nesbakken A, Lothe RA (2019)
High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases
Clin Colorectal Cancer, 19 (1), e26-e47
DOI 10.1016/j.clcc.2019.09.003, PubMed 31982351

Guren MG (2019)
The global challenge of colorectal cancer
Lancet Gastroenterol Hepatol, 4 (12), 894-895
DOI 10.1016/S2468-1253(19)30329-2, PubMed 31648973

Rusten E, Rekstad BL, Undseth C, Klotz D, Hernes E, Guren MG, Malinen E (2019)
Anal cancer chemoradiotherapy outcome prediction using ¹⁸F-fluorodeoxyglucose positron emission tomography and clinicopathological factors
Br J Radiol, 92 (1097), 20181006
DOI 10.1259/bjr.20181006, PubMed 30810343

Röhrl K, Guren MG, Astrup GL, Småstuen MC, Rustøen T (2019)
High symptom burden is associated with impaired quality of life in colorectal cancer patients during chemotherapy:A prospective longitudinal study
Eur J Oncol Nurs, 44, 101679
DOI 10.1016/j.ejon.2019.101679, PubMed 31751848

Röhrl K, Guren MG, Småstuen MC, Rustøen T (2019)
Symptoms during chemotherapy in colorectal cancer patients
Support Care Cancer, 27 (8), 3007-3017
DOI 10.1007/s00520-018-4598-y, PubMed 30607676

Smeby J, Sveen A, Bergsland CH, Eilertsen IA, Danielsen SA, Eide PW, Hektoen M, Guren MG, Nesbakken A, Bruun J, Lothe RA (2019)
Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer
ESMO Open, 4 (3), e000523
DOI 10.1136/esmoopen-2019-000523, PubMed 31321083

Smeby J, Sveen A, Eilertsen IA, Danielsen SA, Hoff AM, Eide PW, Johannessen B, Hektoen M, Skotheim RI, Guren MG, Nesbakken A, Lothe RA (2019)
Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer
Oncogenesis, 8 (6), 35
DOI 10.1038/s41389-019-0141-3, PubMed 31092812

Publications 2018

Benitez Majano S, Di Girolamo C, Rachet B, Maringe C, Guren MG, Glimelius B, Iversen LH, Schnell EA, Lundqvist K, Christensen J, Morris M, Coleman MP, Walters S (2018)
Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study
Lancet Oncol, 20 (1), 74-87
DOI 10.1016/S1470-2045(18)30646-6, PubMed 30545752

Bruun J, Sveen A, Barros R, Eide PW, Eilertsen I, Kolberg M, Pellinen T, David L, Svindland A, Kallioniemi O, Guren MG, Nesbakken A, Almeida R, Lothe RA (2018)
Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer
Mol Oncol, 12 (9), 1639-1655
DOI 10.1002/1878-0261.12347, PubMed 29900672

Claassen YHM, Vermeer NCA, Iversen LH, van Eycken E, Guren MG, Mroczkowski P, Martling A, Codina Cazador A, Johansson R, Vandendael T, Wibe A, Moller B, Lippert H, Rutten HJT, Portielje JEA, Liefers GJ, Holman FA, van de Velde CJH, Bastiaannet E (2018)
Treatment and survival of rectal cancer patients over the age of 80 years: a EURECCA international comparison
Br J Cancer, 119 (4), 517-522
DOI 10.1038/s41416-018-0215-6, PubMed 30057408

Guren MG, Aagnes B, Nygård M, Dahl O, Møller B (2018)
Rising Incidence and Improved Survival of Anal Squamous Cell Carcinoma in Norway, 1987-2016
Clin Colorectal Cancer, 18 (1), e96-e103
DOI 10.1016/j.clcc.2018.10.001, PubMed 30415990

Smeby J, Sveen A, Merok MA, Danielsen SA, Eilertsen IA, Guren MG, Dienstmann R, Nesbakken A, Lothe RA (2018)
CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer
Ann Oncol, 29 (5), 1227-1234
DOI 10.1093/annonc/mdy085, PubMed 29518181

Vermeer NCA, Claassen YHM, Derks MGM, Iversen LH, van Eycken E, Guren MG, Mroczkowski P, Martling A, Johansson R, Vandendael T, Wibe A, Moller B, Lippert H, Portielje JEA, Liefers GJ, Peeters KCMJ, van de Velde CJH, Bastiaannet E (2018)
Treatment and Survival of Patients with Colon Cancer Aged 80 Years and Older: A EURECCA International Comparison
Oncologist, 23 (8), 982-990
DOI 10.1634/theoncologist.2017-0551, PubMed 29567826

Publications 2017

Astrup GL, Hofsø K, Bjordal K, Guren MG, Vistad I, Cooper B, Miaskowski C, Rustøen T (2017)
Patient factors and quality of life outcomes differ among four subgroups of oncology patients based on symptom occurrence
Acta Oncol, 56 (3), 462-470
DOI 10.1080/0284186X.2016.1273546, PubMed 28077018

Byskov CS, Nyvang L, Guren MG, Spindler KLG, Muren LP (2017)
The normal tissue sparing potential of an adaptive plan selection strategy for re-irradiation of recurrent rectal cancer
Phys. Imag. Radiat. Oncol., 3, 43-48
DOI 10.1016/j.phro.2017.09.001

Labori KJ, Guren MG, Brudvik KW, Røsok BI, Waage A, Nesbakken A, Larsen S, Dueland S, Edwin B, Bjørnbeth BA (2017)
Resection of synchronous liver metastases between radiotherapy and definitive surgery for locally advanced rectal cancer: short-term surgical outcomes, overall survival and recurrence-free survival
Colorectal Dis, 19 (8), 731-738
DOI 10.1111/codi.13622, PubMed 28181384

Rusten E, Rekstad BL, Undseth C, Al-Haidari G, Hanekamp B, Hernes E, Hellebust TP, Malinen E, Guren MG (2017)
Target volume delineation of anal cancer based on magnetic resonance imaging or positron emission tomography
Radiat Oncol, 12 (1), 147
DOI 10.1186/s13014-017-0883-z, PubMed 28874205

Sodergren SC, Johnson CD, Gilbert A, Tomaszewski KA, Chu W, Chung HT, Dennis K, Desideri I, Glynne-Jones R, Grønlie Guren M, Kardamakis D, Nugent K, Schmidt H, Sebag-Montefiore D, Vassiliou V, EORTC Quality of Life Group (2017)
Phase I-III development of the EORTC QLQ-ANL27, a health-related quality of life questionnaire for anal cancer
Radiother Oncol, 126 (2), 222-228
DOI 10.1016/j.radonc.2017.11.018, PubMed 29217122

Thomsen M, Guren MG, Skovlund E, Glimelius B, Hjermstad MJ, Johansen JS, Kure E, Sorbye H, Pfeiffer P, Christoffersen T, Guren TK, Tveit KM (2017)
Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status
Eur J Cancer, 81, 26-35
DOI 10.1016/j.ejca.2017.04.026, PubMed 28595137

Åsli LM, Johannesen TB, Myklebust TÅ, Møller B, Eriksen MT, Guren MG (2017)
Preoperative chemoradiotherapy for rectal cancer and impact on outcomes - A population-based study
Radiother Oncol, 123 (3), 446-453
DOI 10.1016/j.radonc.2017.04.012, PubMed 28483302

Publications 2016

Cameron MG, Kersten C, Vistad I, van Helvoirt R, Weyde K, Undseth C, Mjaaland I, Skovlund E, Fosså SD, Guren MG (2016)
Palliative pelvic radiotherapy for symptomatic rectal cancer - a prospective multicenter study
Acta Oncol, 55 (12), 1400-1407
DOI 10.1080/0284186X.2016.1191666, PubMed 27332723

Glimelius B, Myklebust TÅ, Lundqvist K, Wibe A, Guren MG (2016)
Two countries - Two treatment strategies for rectal cancer
Radiother Oncol, 121 (3), 357-363
DOI 10.1016/j.radonc.2016.11.010, PubMed 27887734

Røhrl K, Guren MG, Miaskowski C, Cooper BA, Diep LM, Rustøen T (2016)
No Differences in Symptom Burden Between Colorectal Cancer Patients Receiving Curative Versus Palliative Chemotherapy
J Pain Symptom Manage, 52 (4), 539-547
DOI 10.1016/j.jpainsymman.2016.04.008, PubMed 27470003

Publications 2015

Cameron MG, Kersten C, Vistad I, van Helvoirt R, Weyde K, Undseth C, Mjaaland I, Skovlund E, Fosså SD, Guren MG (2015)
Palliative pelvic radiotherapy for symptomatic incurable prostate cancer – A prospective multicenter study
Radiother Oncol, 115 (3), 314-20
DOI 10.1016/j.radonc.2015.05.021, PubMed 26091575

Guren MG, Kørner H, Pfeffer F, Myklebust TÅ, Eriksen MT, Edna TH, Larsen SG, Knudsen KO, Nesbakken A, Wasmuth HH, Vonen B, Hofsli E, Færden AE, Brændengen M, Dahl O, Steigen SE, Johansen MJ, Lindsetmo RO, Drolsum A, Tollåli G, Dørum LM, Møller B, Wibe A (2015)
Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993-2010
Acta Oncol, 54 (10), 1714-22
DOI 10.3109/0284186X.2015.1034876, PubMed 25924970

Labori KJ, Schulz A, Drolsum A, Guren MG, Kløw NE, Bjørnbeth BA (2015)
Radiofrequency ablation of unresectable colorectal liver metastases: trends in management and outcome during a decade at a single center
Acta Radiol Open, 4 (7), 2058460115580877
DOI 10.1177/2058460115580877, PubMed 26346740

Leon O, Guren MG, Radu C, Gunnlaugsson A, Johnsson A (2015)
Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer
Eur J Cancer, 51 (18), 2740-6
DOI 10.1016/j.ejca.2015.08.029, PubMed 26597443

Walters S, Benitez-Majano S, Muller P, Coleman MP, Allemani C, Butler J, Peake M, Guren MG, Glimelius B, Bergström S, Påhlman L, Rachet B (2015)
Is England closing the international gap in cancer survival?
Br J Cancer, 113 (5), 848-60
DOI 10.1038/bjc.2015.265, PubMed 26241817

Publications 2014

Guren MG, Undseth C, Rekstad BL, Brændengen M, Dueland S, Spindler KL, Glynne-Jones R, Tveit KM (2014)
Reirradiation of locally recurrent rectal cancer: a systematic review
Radiother Oncol, 113 (2), 151-7
DOI 10.1016/j.radonc.2014.11.021, PubMed 25613395

Leon O, Guren M, Hagberg O, Glimelius B, Dahl O, Havsteen H, Naucler G, Svensson C, Tveit KM, Jakobsen A, Pfeiffer P, Wanderås E, Ekman T, Lindh B, Balteskard L, Frykholm G, Johnsson A (2014)
Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines
Radiother Oncol, 113 (3), 352-8
DOI 10.1016/j.radonc.2014.10.002, PubMed 25499203

Publications 2013

Bentzen AG, Balteskard L, Wanderås EH, Frykholm G, Wilsgaard T, Dahl O, Guren MG (2013)
Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors
Acta Oncol, 52 (4), 736-44
DOI 10.3109/0284186X.2013.770599, PubMed 23438358

Bentzen AG, Guren MG, Vonen B, Wanderås EH, Frykholm G, Wilsgaard T, Dahl O, Balteskard L (2013)
Faecal incontinence after chemoradiotherapy in anal cancer survivors: long-term results of a national cohort
Radiother Oncol, 108 (1), 55-60
DOI 10.1016/j.radonc.2013.05.037, PubMed 23891095

Braendengen M, Guren MG, Glimelius B (2013)
Target Volume Definition in Rectal Cancer: What Is the Best Imaging Modality?
Curr. Colorectal Cancer Rep., 9 (2), 116-125
DOI 10.1007/s11888-013-0170-9

Cameron MG, Kersten C, Guren MG, Fosså SD, Vistad I (2013)
Palliative pelvic radiotherapy of symptomatic incurable prostate cancer - a systematic review
Radiother Oncol, 110 (1), 55-60
DOI 10.1016/j.radonc.2013.08.008, PubMed 24044801

Cameron MG, Kersten C, Vistad I, Fosså S, Guren MG (2013)
Palliative pelvic radiotherapy of symptomatic incurable rectal cancer - a systematic review
Acta Oncol, 53 (2), 164-73
DOI 10.3109/0284186X.2013.837582, PubMed 24195692

Sveen A, Nesbakken A, Ågesen TH, Guren MG, Tveit KM, Skotheim RI, Lothe RA (2013)
Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving?
Clin Cancer Res, 19 (24), 6669-77
DOI 10.1158/1078-0432.CCR-13-1769, PubMed 24166914

Publications 2012

Amdal CD, Jacobsen AB, Guren MG, Bjordal K (2012)
Patient-reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: a systematic review
Acta Oncol, 52 (4), 679-90
DOI 10.3109/0284186X.2012.731521, PubMed 23190360

Bentzen AG, Guren MG, Wanderås EH, Frykholm G, Tveit KM, Wilsgaard T, Dahl O, Balteskard L (2012)
Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort
Int J Radiat Oncol Biol Phys, 83 (2), e173-80
DOI 10.1016/j.ijrobp.2011.12.062, PubMed 22436791

Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U (2012)
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study
Ann Oncol, 24 (1), 152-60
DOI 10.1093/annonc/mds276, PubMed 22967994

Publications 2010

Bruheim K, Tveit KM, Skovlund E, Balteskard L, Carlsen E, Fosså SD, Guren MG (2010)
Sexual function in females after radiotherapy for rectal cancer
Acta Oncol, 49 (6), 826-32
DOI 10.3109/0284186X.2010.486411, PubMed 20615170

Marienhagen K, Helland A, Nordberg T, Guren MG, Hofsli E (2010)
[How do Norwegian oncologists perceive their working conditions?]
Tidsskr Nor Laegeforen, 130 (5), 487-9
DOI 10.4045/tidsskr.08.0305, PubMed 20224615

Publications 2009

Bruheim K, Guren MG, Dahl AA, Skovlund E, Balteskard L, Carlsen E, Fosså SD, Tveit KM (2009)
Sexual function in males after radiotherapy for rectal cancer
Int J Radiat Oncol Biol Phys, 76 (4), 1012-7
DOI 10.1016/j.ijrobp.2009.03.075, PubMed 19880263

Bruheim K, Guren MG, Skovlund E, Hjermstad MJ, Dahl O, Frykholm G, Carlsen E, Tveit KM (2009)
Late side effects and quality of life after radiotherapy for rectal cancer
Int J Radiat Oncol Biol Phys, 76 (4), 1005-11
DOI 10.1016/j.ijrobp.2009.03.010, PubMed 19540058

Publications 2008

Bruheim K, Svartberg J, Carlsen E, Dueland S, Haug E, Skovlund E, Tveit KM, Guren MG (2008)
Radiotherapy for rectal cancer is associated with reduced serum testosterone and increased FSH and LH
Int J Radiat Oncol Biol Phys, 70 (3), 722-7
DOI 10.1016/j.ijrobp.2007.10.043, PubMed 18262088

Publications 2006

Guren MG, Tobiassen LB, Trygg KU, Drevon CA, Dueland S (2006)
Dietary intake and nutritional indicators are transiently compromised during radiotherapy for rectal cancer
Eur J Clin Nutr, 60 (1), 113-9
DOI 10.1038/sj.ejcn.1602274, PubMed 16205744

Publications 2005

Guren MG (2005)
Rectal cancer - quality of life and side effects associated with radiotherapy and surgery
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 262, 1 b. (flere pag.)
BIBSYS 050522833, ISBN 82-8072-190-8

Guren MG, Eriksen MT, Wiig JN, Carlsen E, Nesbakken A, Sigurdsson HK, Wibe A, Tveit KM, Norwegian Rectal Cancer Group (2005)
Quality of life and functional outcome following anterior or abdominoperineal resection for rectal cancer
Eur J Surg Oncol, 31 (7), 735-42
DOI 10.1016/j.ejso.2005.05.004, PubMed 16180267

Sauer T, Guren MG, Noren T, Dueland S (2005)
Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy?
Histopathology, 47 (6), 560-4
DOI 10.1111/j.1365-2559.2005.02252.x, PubMed 16324192

Publications 2004

Guren MG, Schneede J, Tveit KM, Ueland PM, Nexø E, Dueland S (2004)
Biochemical signs of impaired cobalamin status during and after radiotherapy for rectal cancer
Int J Radiat Oncol Biol Phys, 60 (3), 807-13
DOI 10.1016/j.ijrobp.2004.04.018, PubMed 15465197

Publications 2003

Dueland S, Guren MG, Olsen DR, Poulsen JP, Magne Tveit K (2003)
Radiation therapy induced changes in male sex hormone levels in rectal cancer patients
Radiother Oncol, 68 (3), 249-53
DOI 10.1016/s0167-8140(03)00120-8, PubMed 13129632

Guren MG, Dueland S, Skovlund E, Fosså SD, Poulsen JP, Tveit KM (2003)
Quality of life during radiotherapy for rectal cancer
Eur J Cancer, 39 (5), 587-94
DOI 10.1016/s0959-8049(02)00741-4, PubMed 12628837

Publications 2001

Guren MG, Wiig JN, Dueland S, Tveit KM, Fosså SD, Waehre H, Giercksky KE (2001)
Quality of life in patients with urinary diversion after operation for locally advanced rectal cancer
Eur J Surg Oncol, 27 (7), 645-51
DOI 10.1053/ejso.2001.1195, PubMed 11669593